Format

Send to:

Choose Destination
See comment in PubMed Commons below
Drug Ther Bull. 2012 Jan;50(1):6-8. doi: 10.1136/dtb.2011.02.0080.

Denosumab for postmenopausal osteoporosis?

[No authors listed]

Abstract

Osteoporosis is the most common clinical disorder of bone metabolism, and is characterised by low bone mass and deterioration of the microarchitecture of bone tissue that results in increased bone fragility and susceptibility to bone fracture. In the UK, it is estimated that osteoporosis affects over 3 million people and leads to 230,000 fractures per year. It occurs most commonly in postmenopausal women and prevalence increases markedly with age, from 2% in women at 50 years to more than 25% at 80 years of age. Denosumab (Prolia - Amgen) is a monoclonal antibody that decreases bone resorption. It has been licensed in the EU for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and also for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. Here, we review the role of denosumab in the management of postmenopausal osteoporosis.

PMID:
22241889
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk